Henry Ford Health

Henry Ford Health Scholarly Commons
Urology Articles

Urology

6-1-2022

Development and Validation of Dynamic Multivariate Prediction
Models of Sexual Function Recovery in Patients with Prostate
Cancer Undergoing Radical Prostatectomy: Results from the
MUSIC Statewide Collaborative
Nnenaya Agochukwu-Mmonu
Adharsh Murali
Daniela Wittmann
Brian Denton
Rodney L. Dunn

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/urology_articles

Authors
Nnenaya Agochukwu-Mmonu, Adharsh Murali, Daniela Wittmann, Brian Denton, Rodney L. Dunn, James
Montie, James O. Peabody, David Miller, and Karandeep Singh

EUROPEAN UROLOGY OPEN SCIENCE 40 (2022) 1–8

available at www.sciencedirect.com
journal homepage: www.eu-openscience.europeanurology.com

Prostate Cancer

Development and Validation of Dynamic Multivariate Prediction
Models of Sexual Function Recovery in Patients with Prostate Cancer
Undergoing Radical Prostatectomy: Results from the MUSIC
Statewide Collaborative
Nnenaya Agochukwu-Mmonu a,b,*, Adharsh Murali c, Daniela Wittmann d, Brian Denton d,e,
Rodney L. Dunn d, James Montie d, James Peabody f, David Miller d, Karandeep Singh d,g,
on behalf of the Michigan Urological Surgery Improvement Collaborative
a
Department of Urology, New York University, New York, NY, USA; b Department of Population Health, New York University, New York, NY, USA; c Providence
Health and Services, Rentan, WA, USA; d Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA; e Department of Industrial and
Operations Engineering, University of Michigan College of Engineering, Ann Arbor, MI, USA; f Department of Urology, Henry Ford Health System, Detroit, MI,
USA; g Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA

Article info

Abstract

Article history:
Accepted March 23, 2022

Background: Radical prostatectomy (RP) is the most common definitive treatment
for men with intermediate-risk prostate cancer and is frequently complicated by
erectile dysfunction.
Objective: To develop and validate models to predict 12- and 24-month post-RP
sexual function.
Design, setting, and participants: Using Michigan Urological Surgery Improvement
Collaborative (MUSIC) registry data from 2016 to 2021, we developed dynamic,
multivariate, random-forest models to predict sexual function recovery following
RP. Model factors (established a priori) included baseline patient characteristics
and repeated assessments of sexual satisfaction, and Expanded Prostate Cancer
Index Composite 26 (EPIC-26) overall scores and sexual domain questions.
Outcome measurements and statistical analysis: We evaluated three outcomes
related to sexual function: (1) the EPIC-26 sexual domain score (range 0–100); (2)
the EPIC-26 sexual domain score dichotomized at 73 for ‘‘good’’ function; and
(3) a dichotomized variable for erection quality at 12 and 24 months after RP. A
gradient-boosting decision tree was used for the prediction models, which combines many decision trees into a single model. We evaluated the performance of
our model using the root mean squared error (RMSE) and mean absolute error
(MAE) for the EPIC-26 score as a continuous variable, and the area under the receiver
operating characteristic curve (AUC) for the dichotomized EPIC-26 sexual domain
score (SDS) and erection quality. All analyses were conducted using R v3.6.3.
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Results and limitations: We identified 3983 patients at 12 months and 2494
patients at 24 months who were randomized to the derivation cohort at 12 and
24 months, respectively. Using baseline information only, our model predicted
the 12-month EPIC-26 SDS with RMSE of 24 and MAE of 20. The AUC for predicting
EPIC-26 SDS 73 (a previously published threshold) was 0.82. Our model predicted
24-month EPIC-26 SDS with RMSE of 26 and MAE of 21, and AUC for SDS 73 of 0.81.
Inclusion of post-RP data improved the AUC to 0.91 and 0.94 at 12 and 24 months,
respectively. A web tool has also been developed and is available at https://ml4lhs.
shinyapps.io/askmusic_prostate_pro/.
Conclusions: Our model provides a valid way to predict sexual function recovery at
12 and 24 months after RP. With this dynamic, multivariate (multiple outcomes)
model, accurate predictions can be made for decision-making and during survivorship, which may reduce decision regret.
Patient summary: Our prediction model allows patients considering prostate cancer surgery to understand their probability before and after surgery of recovering
their erectile function and may reduce decision regret.
Ó 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Radical prostatectomy (RP) is the treatment most frequently
selected for localized prostate cancer and is curative for
early-stage prostate cancer [1,2]. Although effective from
the perspective of cancer control, RP has nontrivial potential
morbidity. Erectile dysfunction impacts many patients
undergoing RP [3] and is highly correlated with patient satisfaction and decision regret [4,5]. While survival after prostate cancer is the key outcome, some men may be willing to
sacrifice survival to remain potent [6]. In order to ensure that
patients have gains in both quantity and quality of life, sexual function outcomes must not be neglected in the shared
decision-making process.
Prevalence estimates of erectile dysfunction after RP
from population-based studies widely vary and are often
the only data available for counseling patients, but they
do not accurately represent every individual’s erectile
function trajectory following prostate cancer treatment
[7–10]. Compounding this is the fact that patients have
poor ability to anticipate changes in erectile function following RP and may have overly optimistic expectations
[11,12]. A major limitation in decision-making for individuals contemplating treatment for prostate cancer is
the paucity of studies that use contemporary data from
patients treated in diverse practices for individualized
prediction of their own outcomes before and after RP.
As patients with prostate cancer face the reality of their
erectile function after surgery, it is also important to be
able to provide ongoing counseling based on real-time
(ie, postoperative) data to provide realistic expectations,
which may decrease decision regret and facilitate treatment decision-making based on patient preferences.
There is a critical need for tools to predict post-RP erectile function for perioperative patient counseling, shared
decision-making, high-quality and high-value care, and
cancer survivorship.
Existing models for predicting functional outcomes
following prostate cancer surgery have demonstrated

good performance but are only intended for preoperative counseling and do not examine other domains of
sexuality, such as sexual satisfaction [13–16]. Here we
build on that work in predicting erectile function using
novel predictors, preoperative data, and postoperative
data in a ‘‘dynamic’’ prediction model that may have
high utility for prostate cancer survivorship. In this context, we used data from the Michigan Urological Surgery
Improvement Collaborative (MUSIC) clinical registry to
determine whether routinely collected clinical variables
can reliably predict erectile function outcomes using
machine learning. We specifically use 2-yr longitudinal
data on sexual function to develop an accurate, valid,
and reliable method for predicting sexual function
recovery on the basis of patient-level determinants.
Our findings will provide patients with the ability to
make informed decisions and give clinicians an
evidence-based tool to facilitate shared decision-making
and postoperative counseling, which could potentially
help in reducing decision regret.

2. Patients and methods
2.1.

Data source

MUSIC is a physician-led quality improvement collaborative established
in 2011 in partnership with Blue Cross Blue Shield of Michigan [17]. The
collaborative comprises 46 diverse community and academic urology
practices representing approximately 90% of the urologists in the state.
A major objective of MUSIC is to improve patient-reported outcomes
after RP. MUSIC Patient Reported Outcomes (MUSIC-PRO) is a statewide
web-based system established in 2014 for measuring and improving
outcomes and health-related quality of life (HRQOL) following RP, with
data collection at baseline (before surgery) and at 3, 6, 12, and 24
months after surgery [18]. Prior reports have described the data acquisition and quality control activities in MUSIC [19,20]. Each MUSIC practice
obtained an exemption or approval for collaborative participation from a
local institutional review board.
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2.2.

Study cohort

2.4.4.

3

Model validation

For the EPIC-26 sexual domain score, we evaluated the performance of
The cohort in this study included all men in the MUSIC registry who

our model using the root mean squared error (RMSE) and mean absolute

underwent RP from February 2016 to January 2021 and enrolled in

error (MAE). We used the area under the receiver operating characteris-

MUSIC-PRO. We then divided patients into derivation and validation

tic curve (AUC) to evaluate discrimination of dichotomized EPIC-26 sex-

cohorts using 2:1 random sampling of the overall cohort stratified by

ual domain scores and erection quality. We assessed calibration by

surgeon. Thus, each surgeon was represented in both the derivation

visually comparing predicted values and observed scores using calibra-

and validation cohorts. However, no patient was included in both

tion plots.

cohorts.
2.4.5.

2.3.
2.3.1.

Measures
MUSIC-PRO

Importance of variables

We evaluated the importance of variable (i.e., which predictors were
most predictive) by summing the relative influence of each predictor
across all trees [27].

The MUSIC-PRO survey administered from May 2016 onwards uses the
Expanded Prostate Cancer Index Composite-26 (EPIC-26) instrument

2.4.6.

[21]. Single-item measures from the Patient-Reported Outcome Mea-

Three additional predictors were added to examine changes in model

surement Information System (PROMIS) Interest in Sexual Activity and

performance: surgical volume, nerve-sparing status, and use of erectile

Global Satisfaction with Sex Life subdomains [22,23] are also included

aids.

in the survey. The surveys were administered at baseline (before RP)
and at 3, 6, 12, and 24 months after RP.

Sensitivity analyses

All analyses for the current study were conducted with R v3.6.3, with
models fitted using the h2o package and calibration plots generated
using the runway package for R.

2.3.2.

MUSIC registry

The MUSIC registry includes detailed clinical and demographic informa-

3. Results

tion including patient age, race, prostate specific antigen (PSA), comorbidities, Gleason score, T stage, BMI, nerve sparing (none, unilateral,
and bilateral), surgeon, and MUSIC-PRO survey responses.

2.4.
2.4.1.

Statistical analysis
Predictors

Predictors were established a priori and selected on the basis of prior
studies [7,23,24]. The a priori predictors included age, body mass index,
diabetes, PSA, Gleason grade, prostate volume, EPIC-26 sexual domain
questions and overall score, and the PROMIS Satisfaction with Sex Life
single item measure. The EPIC-26 sexual domain questions and PROMIS
satisfaction were assessed at baseline (before RP) and at 3, 6, 12, and 24
months after RP. A complete list of predictors is included in Supplementary Table 1.

2.4.2.

Outcomes

We evaluated three outcomes related to sexual function: (1) the EPIC-26

3.1.

Sample description

We identified 3983 men with EPIC-26 sexual domain scores
available at 12 months and 2494 with scores available at 24
months. At 12 months, 2653 men were randomized to the
derivation cohort and 1657 to the validation cohort
(Table 1). At 24 months, 1330 men were randomized to
the derivation cohort and 837 to the validation cohort.
The mean age of the cohort was 64 yr in the derivation
cohort and 65 yr in the validation cohort. The median age
was 65 yr in both the derivation cohort and the validation
cohort. The derivation cohort was further randomly subdivided into training and tuning cohorts, with the tuning
cohort used to determine when the model had converged
on the basis of early stopping criteria.
3.2.

Prevalence of outcomes

sexual domain score (range 0–100); (2) the EPIC-26 sexual domain score

3.2.1.

dichotomized at 73 for ‘‘good’’ function; and (3) a dichotomized erec-

At baseline, the median EPIC-26 sexual domain score was
71 (IQR 40–89); 48% of patients had a good domain score,
defined as a score 73. The median sexual domain score
was 22 (IQR 9.5–51) at 12 months after RP and 26 (IQR
13–58) at 24 months, with good domain scores reported
by 13% and 16%, respectively.

tion quality variable at 12 and 24 months following RP. The threshold of
73 for dichotomizing EPIC-26 scores was chosen on the basis of prior
work [25,26]. Good erection quality was defined as ‘‘erections firm
enough for intercourse’’.

2.4.3.

EPIC-26 sexual domain score

Model development

Gradient-boosting decision tree (GBDT) models were used for the pre-

3.2.2.

diction model, in which many decision trees are combined into a single

Good erection quality was reported by 56% at baseline
(1803/3239), 15% (615/3980) of the overall cohort at 12
months after RP, and 19% (496/2494) at 24 months after RP.

model. Predictions made by combining decision trees together results in
greater accuracy. We constructed two GBDT models: one to predict EPIC-

Erection quality

26 outcomes at 12 and 24 months after RP, and one to predict erection
quality at 12 and 24 months after RP. We refer to the models as dynamic

3.3.

Model performance in the validation cohort

because they can make 12-month and 24-month predictions at different
time points using continuously collected data beyond the baseline/pre-

3.3.1.

operative time point (e.g., at baseline/preoperative, 3 months/postoper-

Using baseline information only, our model predicted the
EPIC-26 sexual domain score at 12 months with RMSE of
24 and MAE of 20 (Table 2). The AUC for predicting a sexual
domain score 73 was 0.82 (Table 2 and Supplementary
Fig. 1). On inclusion of post-RP data at 3 and 6 months,

ative), and as multivariate because they predict outcomes at multiple
time points (e.g., 12 and 24 months after RP). Uncertainty in the EPIC26 outcomes was estimated using GBDTs trained to predict the 2.5th
and 97.5th percentiles for EPIC-26 scores.

EPIC-26 sexual domain score at 12 months

4
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Table 1 – Patient characteristics for predictors and outcomes by cohort and outcome time
Characteristic

a

Derivation cohort

Age (yr)
Body mass index (kg/m2)
Data missing
Diabetes mellitus, n (%)
Data missing
Prostate volume (cm3)
Data missing
Prostate-specific antigen (ng/ml)
Data missing
Gleason grade group, n (%)
Grade group 1
Grade group 2
Grade group 3
Grade group 4
Grade group 5
Data missing
Sexual satisfaction at baseline, n (%)
1
2
3
4
5
Data missing
EPIC-26 SDS at baseline
Data missing
EPIC-26 SDS after RP
High erection quality after RP, n (%)
Data missing

Validation cohort

12-mo outcome
(N = 2653)

24-mo outcome
(N = 1657)

12-mo outcome
(N = 1330)

24-mo outcome
(N = 837)

65 (60–69)
28.7 (26.1–32.2)
538
200 (9.4)
515
37 (28–49)
824
6.5 (4.8–9.4)
824

65 (60–69)
28.6 (25.9–32.3)
363
121 (9.2)
348
37 (28–50)
469
6.4 (4.7–9.3)
469

65 (60–69)
28.7 (26.2–32.1)
274
118 (11)
262
36 (28–49)
461
6.3 (4.8–9.5)
403

65 (60–69)
28.4 (26.1–31.8)
179
63 (9.5)
172
36 (29–48)
297
6.2 (4.8–9.8)
237

343 (15)
1,012 (44)
532 (23)
265 (11)
171 (7.6)
330

231
632
319
174
114
187

168 (14)
557 (47)
261 (22)
123 (10)
79 (6.6)
142

126 (16)
345 (45)
159 (21)
82 (11)
54 (7.0)
71

40 (2.7)
128 (8.6)
347 (23)
523 (35)
455 (30)
1160
71 (40–88)
537
22 (10–50)
412 (16)
3

18 (1.8)
82 (8.4)
237 (24)
338 (35)
304 (31)
678
72 (42–91)
267
25 (12–57)
318 (19)
0

21 (2.9)
58 (8.0)
168 (23)
248 (34)
230 (32)
605
71 (40–92)
263
22 (9.0–53)
203 (15)
0

9 (1.9)
31 (6.6)
113 (24)
160 (34)
157 (33)
367
75 (46–92)
129
26 (12–62)
178 (21)
0

(16)
(43)
(22)
(12)
(7.8)

EPIC-26 = Expanded Prostate Cancer Index Composite-26; RP = radical prostatectomy; SDS = sexual domain score.
a
Data for continuous variables are presented as the median (interquartile range).

Table 2 – Model performance for the EPIC-26 sexual domain score and erection quality
Outcome and time

Data for patient-reported predictors
BL

EPIC-26 sexual domain score
12 mo

3 mo

Model performance

6 mo

12 mo

RMSE

MAE

AUC

X
X

24
21
19
17
26
23
21
17
17

20
16
14
13
21
18
16
12
13

0.82
0.85
0.89
0.91
0.81
0.84
0.88
0.93
0.94

X
X
X
X

24 mo

X

X
X

X
X
X
Erection quality
12 mo

X

X

X

0.80
0.82
0.86
0.89
0.81
0.85
0.88
0.92
0.92

X

24 mo

X
X

X

X
X

X
X
X

X

X
X

X

AUC = area under the receiver operating characteristic curve; BL = baseline; EPIC-26 = Expanded Prostate Cancer Index Composite-26; MAE = mean absolute
error; RMSE = root mean squared error.

RMSE improved to 17, MAE improved to 13, and AUC
improved to 0.91.

of post-RP data for 3, 6, and 12 months, RMSE improved to
17, MAE improved to 12, and AUC improved to 0.94.

3.3.2.

3.3.3.

EPIC-26 sexual domain score at 24 months

Using baseline information only, our model predicted the
EPIC-26 sexual domain score at 24 months with RMSE of
26 and MAE of 21, and an AUC for sexual domain score
73 of 0.81 (Table 2 and Supplementary Fig. 2). On inclusion

Erection quality at 12 months

Using baseline information only, our model predicted good
erection quality at 12 months, with an AUC of 0.80, which
improved to 0.89 on inclusion of post-RP data at 3 and 6
months (Table 2).
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3.3.4.

5

Erection quality at 24 months

Using baseline information only, our model predicted good
erection quality at 24 months, with an AUC of 0.81, which
improved to 0.92 on inclusion of post-RP data at 3 and 6
months (Table 2).
3.3.5.

Model calibration

The model predicting the EPIC-26 sexual domain score was
well calibrated at 12 and 24 months according to the fit of a
local regression curve (Fig. 1). The model predicting erection quality appeared to be well calibrated at 12 months
but underpredicted the probability of good erection quality
at 24 months (Fig. 2).
3.3.6.

Importance of variables

Shapley value plots are provided in Supplementary Figs. 3–
6 for the EPIC-26 sexual domain score and erection quality,
with separate plots provided for factors important at baseline and at 6 mo after surgery. The two most important factors for predicting the 24-month EPIC-26 sexual domain
score at baseline were the baseline sexual domain score
and age. At 6 month after surgery, the most important factor was the 6-month sexual domain score, with age remaining as the second most important variable. The same
variables were also the two most important variables for
predicting good erectile quality, although age was the most
important factor. We examined the impact of surgeon volume and noted it did not improve the model beyond
patient-level determinants.
3.3.7.

Sensitivity analyses

The model performance was unchanged or minimally
improved on addition of predictors including surgical volume, nerve-sparing status, and erectile aids. For example,
addition of surgical volume did not improve prediction of

Fig. 2 – Calibration of the model predicting high erection quality at 12 and
24 mo for the validation cohort using baseline information only with locally
weighted scatterplot smoothing and a density plot of predicted scores
below.

the EPIC-26 score at 24 months using baseline data (RMSE
26, MAE 21, AUC 0.81) but did slightly improve the RMSE
(from 17 to 16) when predicting using complete data
through 12 months. Inclusion of nerve-sparing status similarly improved the RMSE from 17 to 16 when using complete
data through 12 months to predict 24-month outcomes.
For the impact of erectile aid use, we first examined the
prevalence of erectile aid use and then investigated model
performance on inclusion of erectile aids. At 12 months,
11.3% (n = 187) of patients reported use of a vacuum erection device, 7.9% (n = 131) reported use of intracavernosal
injections, and 32.2% (n = 533) reported use of
phosphodiesterase-5 inhibitors, while 59.0% reported no
use of any erectile aids (n = 978). Some patients used multiple erectile aids, hence the proportions do not sum to
100%. Inclusion of erectile aid use improved the RMSE from
17 to 16 when using complete data through 12 months to
predict 24-month outcomes but not at baseline.
Inclusion of all the new predictors (surgical volume,
nerve sparing, and erectile aid use) in a final model did
not significantly improve the 24-month EPIC-26 score outcome. With the addition of these variables, the model had
similar performance at baseline (RMSE 26, MAE 22, AUC
0.81) and with complete information through 12 months
(RMSE 17, MAE 12, AUC 0.93).
4. Discussion

Fig. 1 – Calibration of the model predicting EPIC-26 sexual domain score for
the validation cohort using baseline information only at 12 and 24 mo with
locally weighted scatterplot smoothing and a density plot of predicted
scores below.

We developed a dynamic model for predicting recovery of
sexual function among patients undergoing RP. Our model
exhibits good performance for preoperative predictions
and even better performance for dynamic predictions,
which facilitates the provision of realistic expectations for
patients preoperatively and during the survivorship period.
Although the dynamic component of the model may not
impact patients’ decision-making for surgery, the dynamic
component of the tool may potentially reduce decision
regret and reassure patients who have experienced only

6
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partial recovery of sexual function in the early postoperative period. For example, using the baseline model, a patient
with a preoperative EPIC-26 sexual domain score of 57
would be predicted to have a 24-mo domain score of 46
(Supplementary Table 2). However, using the dynamic
model, a patient with the same characteristics and a score
of 57 at 6 months after surgery would be expected to ultimately end up with a score of 81 on the basis of their
expected recovery trajectory.
While most prediction models in prostate cancer have
focused on survival-related outcomes (eg, margin status,
disease free survival) [28,29], patients undergoing RP do
have a strong focus on sexual function, which should be
carefully considered in the decision-making process.
Patients put themselves at substantial risk in pursuit of
cancer-free status; prediction of erectile function outcomes
improves their ability to evaluate the tradeoffs involved in
RP and gives clarity regarding realistic postoperative goals.
Our model improves on models previously developed by
other investigators [13,14]. A 2011 prediction model had
AUC of 0.77 for predicting 24-month erection quality in an
RP cohort (n = 524) [14]. In comparison, our model was
developed on a fourfold larger cohort (n = 4115 at 12
months and n = 2313 at 24 months), achieves a higher
AUC (0.80), and can provide updated predictions for 24
months at the 12-month mark with even more precision
(AUC 0.88; Table 2). A more recent model predicted the 5yr EPIC-26 sexual domain score with RMSE of 26 and MAE
of 21 using data from the CEASAR registry [13]. Our study
also predicts erection quality, which is notable given that
this outcome may be more interpretable by patients. Addition of postoperative information improved the RMSE to 18
and MAE to 13 for the model, highlighting how the dynamic
component of the model can tailor predictions further during the survivorship period. Predictors are similar between
this model and previously described models with the
exception of a novel predictor in our model, PROMIS Satisfaction with Sex Life, which we have previously described
as an important component of sexuality for prostate cancer
survivors [23]. To increase the utility of the model, we did
not include nerve sparing in this model given that the
extent of nerve sparing that will be performed is unknown
at baseline (ie, before surgery) and nerve sparing varies by
individual surgeon; our model focuses on patient-level
determinants. In addition, sensitivity analyses demonstrated that inclusion of nerve sparing did not improve
the model performance.
Our study does have limitations. We only evaluated practices in the state of Michigan, although the practices had
diverse patient cohorts, sizes, and provider types, including
both high- and low-volume surgeons. We did not include
outcomes beyond 24 months. Although recovery of sexual
function is uncommon beyond 24 months, there is some evidence that sexual activity recovery after surgery in some
cases peaks at 3–6 yr after surgery [30,31]. In addition, this
model is only applicable to patients considering RP and does
not predict sexual function following other prostate cancer
treatments such as radiation therapy. We acknowledge that
patients have a choice of more than one therapy (eg, RP,
radiotherapy, active surveillance), all of which differ in their

impact on HRQOL [32–36]. RP has the most deleterious
effect on sexual function, an important component of
HRQOL, and therefore patients considering RP would benefit
the most from a prediction model for sexual function recovery [37]. Lastly, we did not include the impact of the surgeon
in the final model. We examined the impact of surgeon volume and noted it did not improve the model performance
beyond patient-level determinants. Thus, we focused on
patient-oriented factors to make our work more generalizable. The model nonetheless has excellent performance
and omission of this variable gives the model expanded utility (i.e., for use in practice settings outside of MUSIC).
Despite these limitations, our findings have significant
implications for patients, providers, policymakers, and hospital leaders. The results have immediate relevance for
patients facing therapy decisions for early-stage prostate
cancer. For the first time, we have produced a dynamic
model that allows personalized prediction of sexual function
recovery before and after surgery. This may be most relevant
for patients for whom preoperative assessment suggests
that sexual function is their most important recovery
domain. Providers can now, in an evidence-based way, support patients in making informed decisions and provide an
individualized sexual function trajectory during survivorship. These results are important for policymakers and hospital leaders who are looking at ways to assess quality.
Evidence-based precision tools for predicting outcomes
can be used to improve outcomes and facilitate the provision
of high-quality care. We have the unique opportunity to
change the face of the delivery of prostate cancer care from
decision-making to survivorship with precision medicine.
While survival and oncologic outcomes are critical and at
the forefront, patients who are cured of their prostate cancer
with RP deserve an evidence-based way to understand the
impact of surgery and treatments on their sexual function.
A user-friendly prototype has been developed for utilization.

5. Conclusions
An evidence-based, personalized approach to understanding
the impact of RP on sexual function and to guide decisionmaking is imperative. In this study we developed and validated a dynamic model to predict sexual function before
and after RP using real-time inputs. If patients are provided
with realistic expectations and a personalized approach to
predicting sexual function before and after surgery, patients
may have lower decision regret, better evidence-based
decision-making, and a better understanding of their individual trajectory for sexual function recovery after RP.
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